APOB and metabolic syndrome: The ARCHES-2 (Study of ARO-ANG3 in Adults with Mixed Dyslipidemia) phase II b study demonstrated that ARO-ANG3 significantly decreased ANGPTL3 expression and atherogenic triglyceride-rich lipoproteins, LDL-C and total apoB, in patients with mixed dyslipidemia [73].